Search | Clinical Trials Finder

Conditions: Multiple Myeloma
Interventions: Thalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma
Interventions: filgrastim, carmustine, cyclophosphamide, cytarabine, dexamethasone, etoposide, mitoxantrone hydrochloride, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Dexamethasone, Daratumumab, autologous hematopoietic cell transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 101
States / cities: Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more

Conditions: Multiple Myeloma
Interventions: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 67
States / cities: Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more

Conditions: Amyloidosis
Interventions: Bortezomib, Dexamethasone, Melphalan; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Detroit, Michigan

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 531
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: Multiple Myeloma, Amyloidosis
Interventions: DaraVRD/DaraVCD; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Myeloma
Interventions: TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more

Conditions: Multiple Myeloma
Interventions: Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Myeloma
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more

Conditions: Multiple Myeloma
Interventions: Revlimid, Velcade, dexamethasone, Farydak; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • Pembroke Pines, Florida • Atlanta, Georgia + 2 more

Conditions: Multiple Myeloma
Interventions: Iberdomide, Daratumumab, Dexamethasone, Carfilzomib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: clarithromycin, thalidomide, dexamethasone; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Isatuximab, Lenalidomide; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Multiple Myeloma
Interventions: KRdD followed by auto-HCT, KRdD only; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more

Conditions: Myeloma, Multiple
Interventions: Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 496
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 337 more

Conditions: Leukemia
Interventions: sargramostim, busulfan, cyclophosphamide, dexamethasone, etoposide, bone marrow transplantation, hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft; Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic
Interventions: Etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase, chemotherapy, intrathecal chemotherapy, steroid therapy, Hematopoietic Stem Cell Transplant, Natural Killer (NK) Cell Transplant; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Search by objective public record fields.

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Elimination of Minimal Residual Disease After Transplant

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia